PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 273 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 3.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $4,253,702 | -26.5% | 110,171 | +1.2% | 0.08% | -29.1% |
| Q3 2022 | $5,789,000 | +160.2% | 108,837 | +185.2% | 0.11% | +80.3% |
| Q2 2022 | $2,225,000 | -78.4% | 38,159 | -71.7% | 0.06% | -77.8% |
| Q1 2022 | $10,305,000 | +48.8% | 135,027 | +17.3% | 0.28% | +27.9% |
| Q4 2021 | $6,925,000 | +36.2% | 115,097 | +26.8% | 0.22% | +49.3% |
| Q3 2021 | $5,084,000 | -11.3% | 90,782 | -3.9% | 0.14% | -26.2% |
| Q2 2021 | $5,729,000 | +102.5% | 94,418 | +133.9% | 0.20% | +18.9% |
| Q1 2021 | $2,829,000 | +5.7% | 40,362 | -9.8% | 0.16% | -8.4% |
| Q4 2020 | $2,677,000 | +589.9% | 44,742 | +286.4% | 0.18% | +108.1% |
| Q1 2020 | $388,000 | -61.2% | 11,580 | -47.6% | 0.09% | +32.3% |
| Q4 2019 | $1,001,000 | +117.6% | 22,100 | +109.0% | 0.06% | +30.0% |
| Q2 2019 | $460,000 | -60.2% | 10,576 | -55.0% | 0.05% | -90.7% |
| Q3 2018 | $1,155,000 | – | 23,500 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |